241 related articles for article (PubMed ID: 25857595)
21. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
22. Impact of allopurinol on risk of myocardial infarction.
Grimaldi-Bensouda L; Alpérovitch A; Aubrun E; Danchin N; Rossignol M; Abenhaim L; Richette P;
Ann Rheum Dis; 2015 May; 74(5):836-42. PubMed ID: 24395556
[TBL] [Abstract][Full Text] [Related]
23. Changes in Prescription Drug and Health Care Use Over 9 Years After the Large Drug Price Increase for Colchicine.
Ly DP; Giuriato MA; Song Z
JAMA Intern Med; 2023 Jul; 183(7):670-676. PubMed ID: 37155179
[TBL] [Abstract][Full Text] [Related]
24. Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
Roddy E; Bajpai R; Forrester H; Partington RJ; Mallen CD; Clarson LE; Padmanabhan N; Whittle R; Muller S
Ann Rheum Dis; 2023 Dec; 82(12):1618-1625. PubMed ID: 37788904
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System.
Mikuls TR; Soto Q; Petro A; Helget L; Roul P; Sayles H; Cope B; Neogi T; LaMoreaux B; O'Dell JR; England BR
JAMA Netw Open; 2022 Jan; 5(1):e2142347. PubMed ID: 34989795
[TBL] [Abstract][Full Text] [Related]
26. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.
Singh JA; Ramachandaran R; Yu S; Curtis JR
BMC Cardiovasc Disord; 2017 Mar; 17(1):76. PubMed ID: 28288564
[TBL] [Abstract][Full Text] [Related]
27. Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Kwon OC; Hong S; Ghang B; Kim YG; Lee CK; Yoo B
Am J Med; 2017 May; 130(5):583-587. PubMed ID: 28065770
[TBL] [Abstract][Full Text] [Related]
28. Colchicine prescribing and safety monitoring in patients with gout.
Ly J; Gow P; Dalbeth N
N Z Med J; 2007 Nov; 120(1265):U2808. PubMed ID: 18264188
[TBL] [Abstract][Full Text] [Related]
29. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
[TBL] [Abstract][Full Text] [Related]
30. Effects of colchicine use on ischemic and hemorrhagic stroke risk in diabetic patients with and without gout.
Yeh JJ; Kuo IL; Yip HT; Hsueh MY; Hsu CY; Kao CH
Sci Rep; 2022 Jun; 12(1):9195. PubMed ID: 35655077
[TBL] [Abstract][Full Text] [Related]
31. Cancer risk in Korean patients with gout.
Oh YJ; Lee YJ; Lee E; Park B; Kwon JW; Heo J; Moon KW
Korean J Intern Med; 2022 Mar; 37(2):460-467. PubMed ID: 32872748
[TBL] [Abstract][Full Text] [Related]
32. Association of gout medications and risk of cataract: a population-based case-control study.
Li YJ; Perng WT; Tseng KY; Wang YH; Wei JC
QJM; 2019 Nov; 112(11):841-846. PubMed ID: 31286139
[TBL] [Abstract][Full Text] [Related]
33. A new perspective on the pharmacoeconomics of colchicine.
Wertheimer AI; Davis MW; Lauterio TJ
Curr Med Res Opin; 2011 May; 27(5):931-7. PubMed ID: 21370937
[TBL] [Abstract][Full Text] [Related]
34. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Levy GD; Rashid N; Niu F; Cheetham TC
J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
[TBL] [Abstract][Full Text] [Related]
35. Colchicine for the treatment of gout.
Richette P; Bardin T
Expert Opin Pharmacother; 2010 Dec; 11(17):2933-8. PubMed ID: 21050036
[TBL] [Abstract][Full Text] [Related]
36. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.
Primatesta P; Plana E; Rothenbacher D
BMC Musculoskelet Disord; 2011 May; 12():103. PubMed ID: 21599917
[TBL] [Abstract][Full Text] [Related]
37. Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study.
Chu CC; Chen YC; Lin MH; Wu WT; Liu FC; Chen HC; Chou YC; Sun CA
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329085
[TBL] [Abstract][Full Text] [Related]
38. Colorectal Cancer Among Gout Patients Undergoing Colonoscopy.
Slobodnick A; Krasnokutsky S; Lehmann RA; Keenan RT; Quach J; Francois F; Pillinger MH
J Clin Rheumatol; 2019 Dec; 25(8):335-340. PubMed ID: 31764494
[TBL] [Abstract][Full Text] [Related]
39. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
Fang YJ; Chung YL; Lin CL; Lim YP
Biomed Res Int; 2020; 2020():6358954. PubMed ID: 32775432
[TBL] [Abstract][Full Text] [Related]
40. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study.
Lu N; Dubreuil M; Zhang Y; Neogi T; Rai SK; Ascherio A; Hernán MA; Choi HK
Ann Rheum Dis; 2016 Mar; 75(3):547-51. PubMed ID: 25739830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
